Secondary pulmonary alveolar proteinosis in hematologic malignancies

Pulmonary alveolar proteinosis (PAP), characterized by deposition of intra-alveolar PAS positive protein and lipid rich material, is a rare cause of progressive respiratory failure first described by Rosen et al. in 1958. The intra-alveolar lipoproteinaceous material was subsequently proven to have...

Full description

Bibliographic Details
Main Authors: Chakra P. Chaulagain, Monika Pilichowska, Laurence Brinckerhoff, Maher Tabba, John K. Erban
Format: Article
Language:English
Published: Elsevier 2014-12-01
Series:Hematology/Oncology and Stem Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S1658387614000806
id doaj-a13c9bb0fb6f4156b11afb97da3d1cda
record_format Article
spelling doaj-a13c9bb0fb6f4156b11afb97da3d1cda2020-11-24T21:52:57ZengElsevierHematology/Oncology and Stem Cell Therapy1658-38762014-12-0174127135Secondary pulmonary alveolar proteinosis in hematologic malignanciesChakra P. Chaulagain0Monika Pilichowska1Laurence Brinckerhoff2Maher Tabba3John K. Erban4Taussig Cancer Institute of Cleveland Clinic, Department of Hematology/Oncology, Cleveland Clinic in Weston, FL, USA; Corresponding author at: Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd., Weston, FL 33331, USA. Tel.: +1 954 659 5840; fax: +1 954 659 5810.Department of Pathology, Tufts Medical Center Cancer Center & Tufts University School of Medicine, Boston, MA, USADepartment of Surgery, Tufts Medical Center Cancer Center & Tufts University School of Medicine, Boston, MA, USADivision of Critical Care, Pulmonary and Sleep Medicine, Tufts Medical Center Cancer Center & Tufts University School of Medicine, Boston, MA, USADivision of Hematology/Oncology, Tufts Medical Center Cancer Center & Tufts University School of Medicine, Boston, MA, USAPulmonary alveolar proteinosis (PAP), characterized by deposition of intra-alveolar PAS positive protein and lipid rich material, is a rare cause of progressive respiratory failure first described by Rosen et al. in 1958. The intra-alveolar lipoproteinaceous material was subsequently proven to have been derived from pulmonary surfactant in 1980 by Singh et al. Levinson et al. also reported in 1958 the case of 19-year-old female with panmyelosis afflicted with a diffuse pulmonary disease characterized by filling of the alveoli with amorphous material described as “intra-alveolar coagulum”. This is probably the first reported case of PAP in relation to hematologic malignancy. Much progress has been made on PAP first described by Rosen which is currently classified as idiopathic or primary or autoimmune PAP. Idiopathic PAP occurs as a result of auto-antibodies directed against granulocyte–macrophage colony stimulating factor (GM-CSF) impeding the surfactant clearing function of alveolar macrophages leading to progressive respiratory failure. Whole lung lavage and GM-CSF therapy has improved outcomes in patients with idiopathic PAP. Despite major advancement in the management of hematologic malignancy and its complications, little is known about the type of PAP first described by Levinson and now known as secondary PAP; a term also used when PAP occurs due to other causes such as occupational dusts. In this article we review and analyze the limited literature available in secondary PAP due to hematologic malignancies and present a case of PAP associated with chronic lymphocytic leukemia successfully treated with bendamustine and rituximab. Keywords: Secondary pulmonary alveolar proteinosis, Hematologic malignancy, Bronchoalveolar lavage, Opportunistic infections, Hematopoietic stem cell transplantationhttp://www.sciencedirect.com/science/article/pii/S1658387614000806
collection DOAJ
language English
format Article
sources DOAJ
author Chakra P. Chaulagain
Monika Pilichowska
Laurence Brinckerhoff
Maher Tabba
John K. Erban
spellingShingle Chakra P. Chaulagain
Monika Pilichowska
Laurence Brinckerhoff
Maher Tabba
John K. Erban
Secondary pulmonary alveolar proteinosis in hematologic malignancies
Hematology/Oncology and Stem Cell Therapy
author_facet Chakra P. Chaulagain
Monika Pilichowska
Laurence Brinckerhoff
Maher Tabba
John K. Erban
author_sort Chakra P. Chaulagain
title Secondary pulmonary alveolar proteinosis in hematologic malignancies
title_short Secondary pulmonary alveolar proteinosis in hematologic malignancies
title_full Secondary pulmonary alveolar proteinosis in hematologic malignancies
title_fullStr Secondary pulmonary alveolar proteinosis in hematologic malignancies
title_full_unstemmed Secondary pulmonary alveolar proteinosis in hematologic malignancies
title_sort secondary pulmonary alveolar proteinosis in hematologic malignancies
publisher Elsevier
series Hematology/Oncology and Stem Cell Therapy
issn 1658-3876
publishDate 2014-12-01
description Pulmonary alveolar proteinosis (PAP), characterized by deposition of intra-alveolar PAS positive protein and lipid rich material, is a rare cause of progressive respiratory failure first described by Rosen et al. in 1958. The intra-alveolar lipoproteinaceous material was subsequently proven to have been derived from pulmonary surfactant in 1980 by Singh et al. Levinson et al. also reported in 1958 the case of 19-year-old female with panmyelosis afflicted with a diffuse pulmonary disease characterized by filling of the alveoli with amorphous material described as “intra-alveolar coagulum”. This is probably the first reported case of PAP in relation to hematologic malignancy. Much progress has been made on PAP first described by Rosen which is currently classified as idiopathic or primary or autoimmune PAP. Idiopathic PAP occurs as a result of auto-antibodies directed against granulocyte–macrophage colony stimulating factor (GM-CSF) impeding the surfactant clearing function of alveolar macrophages leading to progressive respiratory failure. Whole lung lavage and GM-CSF therapy has improved outcomes in patients with idiopathic PAP. Despite major advancement in the management of hematologic malignancy and its complications, little is known about the type of PAP first described by Levinson and now known as secondary PAP; a term also used when PAP occurs due to other causes such as occupational dusts. In this article we review and analyze the limited literature available in secondary PAP due to hematologic malignancies and present a case of PAP associated with chronic lymphocytic leukemia successfully treated with bendamustine and rituximab. Keywords: Secondary pulmonary alveolar proteinosis, Hematologic malignancy, Bronchoalveolar lavage, Opportunistic infections, Hematopoietic stem cell transplantation
url http://www.sciencedirect.com/science/article/pii/S1658387614000806
work_keys_str_mv AT chakrapchaulagain secondarypulmonaryalveolarproteinosisinhematologicmalignancies
AT monikapilichowska secondarypulmonaryalveolarproteinosisinhematologicmalignancies
AT laurencebrinckerhoff secondarypulmonaryalveolarproteinosisinhematologicmalignancies
AT mahertabba secondarypulmonaryalveolarproteinosisinhematologicmalignancies
AT johnkerban secondarypulmonaryalveolarproteinosisinhematologicmalignancies
_version_ 1725873823518031872